Use of the nested reverse transcription-polymerase chain reaction for the detection of human papillomavirus 16 E6 transcriptional activity in cervical cancer: A technical perspective

Aim: The aim of this study was to evaluate HPV 16 E6 expression using nested RT-PCR in cervical tumour tissue and compare this technique with standard RT-PCR in a group of patients using injectable contraceptive steroids.

Patients and methods: Tumour DNA was analysed for the presence and type of HPV by polymerase chain reaction (PCR) from 120 cervical cancer samples. Ribonucleic acid (RNA) was extracted from cervical tissue samples and cell-lines. Reverse transcription was carried out on all samples using reverse transcriptase enzyme to form single-stranded cDNA. The GAPDH (glyceraldehyde-3-phosphate dehydrogenase) housekeeping gene was used.

Results: The majority of patients had squamous cell carcinoma. Of 120 cervical tissue samples, there were 111 samples with confirmed HPV 16 infection. RNA was extracted in only 86 samples. Of these, 23 samples contained genomic DNA. Of the remaining 63 patients, there were 53 patients who had expression of HPV-type 16. E6 full-length gene expression. In total there were 25 patients (40%) with expression of the HPV 16 E6*I gene and 30 patients with expression of the E6*II gene. The nested PCR method using S1/S2 primers detected 54 patients with the E6*I & E6*II transcripts in comparison to classical PCR which detected only 31 such transcripts.

Conclusion: Nested RT-PCR is the method of choice to determine the role of different E6/E7 splice products in HPV-associated carcinogenesis.

Nested RT-PCR; HPV-related cervical carcinogenesis

[1] Bosch EX., Manos M.M.. Munoz N. et al.: "The International Biological Study on cervical cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective··. J. Natl. Cancer Inst., 1995. 87, 796.

[2] Schiffman M.H., Bauer H.M., Hoover R.N. et al.: "Epidemiologic evidence showing that human papillornavirus infection causes most cervical intraepithelial neoplasia". J. Natl. Cancer Inst., 1993, 85, 958.

[3] Kjaer S.K., vau den Brule A.J.C.. Brock J.E. et al.: "Human papillomavirus: the most significant risk determinant of cervical intraepithelial neoplasia". Int. J. Cancer, 1996, 65, 601.

[4] Herrington C.S.: "Human papillomaviruses and cervical neoplasia I: virology, classification, pathology and epidemiology". J. Clin Pathol., 1994. 47, 1066.

[5] Lechner M.S., Mack D.H., Finicle A.B., Crook T., Voudsen K.H .. Laimins L.A.: "Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-rnediated repression of transcription" EMBO J., 1992, 11, 3045.

[6] Keen N., Elston, R., Crawford L.: "Interaction of the E6 protern of human papillomavirus with cellular proteins". Oncogene, 1994, 9, 1493.

[7] Smotkin D., Wettstein F.O.:'Transcription of human papillomavirus type 16 early genes in a cervical cancer and cancer derived cell line and identification of the E7 protein". Proc. Natl. Acad. Sci USA, 1986, 83, 4680.

[8] Cornelissen M.T., Smits H.L.. Breit M.A., van den Twee! J.G., Struyk A.P., van der Noordaa J., ter Schegget J.: "Uniformity of the splicing pattern of the E6/E7 transcripts in human papillomavirus type 16-transformed human fibroblasts, human cervical premalignant lesions and carcinomas". J. Gen. Viral., 1990, 71. 1243.

[9] Srnotkin D., Prokoph H., Wettstein F.O.:''Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms". J. Virol., 1989, 63, 1441.

[10] Sotlar K., Selinka H.C., Menton M., Kandoff R., Bultmann B. "Detection of human papillomavirus type 16 E6.E7 oncogene transcripts in dysplastic and non-dysplastic cervical scrapes by nested RT-PCR". Gynecol. Oneal., 1998, 69, 114.

[11] Manos M.M., Ting Y.. Wright et al.: "The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses". Cancer Cells, 1989, 7, 209.

[12] Silas F., Levin C.V., Spencer D. et al.: "HlV and cancer in South Africa". S. Afr. Med. J., 1993, 83, 880.

[13] Southern S.A., Herrington C.S.: "Molecular events in uterine cervical cancer". Sex Transm. inf, 1998, 74. 101.

[14] Thomas J.T., Laimins L.A., Ruesch M.N.: "Pertubation of cell cycle control by E6 and E7 oncoproteins of human papi11omaviruses". Papillomavirus Rep., 1998, 9, 59.

[15] Southern S.A.. Herrington C.S.: "Disruption of cell cycle control by human papillomaviruses with special reference to cervical carcinoma". Int. J. Gynecol. Cancer, 2000, 10, 263.

[16] Galloway D.A., McDougall J.K.: "The disruption of cell - cycle checkpoints by papillomavirus oncoproteins contribute to anogenital neoplasia". Cancer Biol., 1996, 7, 309.

[17] Kessis T.D., Slebos R.J., Nelson W.G. et al.: "Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage". Proc. Natl. Acad. Sci USA, 1993, 90, 3988.

[18] Rornanczuk H., Thierry F., Howley P.M.:''Mutational analysis of ClS elements involved in E2 modulation of human papillomavirus type 16 p97 and type 18 p105 promoters". J. Vim/., 1990, 64, 2849.

[19] Rice P.S., Mant C., Cason J. et al.: "High prevalence of human papillomavirus type 16 infection among children". J. Med. Virol., 2000, 61, 70.